Photoresponsive 'chemo-free' phytotherapy: formulation development for the treatment of triple-negative breast cancer

Nanomedicine (Lond). 2024 Jan;19(1):5-24. doi: 10.2217/nnm-2023-0231. Epub 2024 Jan 5.

Abstract

Aim: The present investigation aimed to develop a chemo-free, nanophytosomal system to treat triple-negative breast cancer (TNBC) via a phyto-photo dual treatment strategy. Method: Size, shape, surface analysis, photoprovoked release profile, photothermal stability, (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide assay, apoptotic assay, DNA fragmentation, in vitro cellular uptake evaluation, mitochondrial membrane potential and caspase-3 assay, and photodynamic evaluation. Results: Biological experiments using MDA-MB-231 cells displayed dose-dependent synergistic anti-TNBC activity of PhytoS/Houttuynia cordata extract (HCE)/IR780 as compared with Phyto/HCE, PhytoS/IR780 and even more promising under laser treatment. Apoptotic assay and DNA fragmentation analysis also showed enhanced anti-TNBC effects. Investigation found that HCE acts via suppression of mitochondrial membrane potential and inducing caspase-3 activity in cells. Conclusion: Our findings suggested that photo-empowered phytotherapy can be employed effectively and safely against TNBC.

Keywords: IR780; photodynamic therapy; photothermal therapy; phytotherapy; plant extract; triple-negative breast cancer.

MeSH terms

  • Caspase 3
  • Cell Line, Tumor
  • Dieldrin / analogs & derivatives*
  • Humans
  • Indoles
  • Phytotherapy
  • Triple Negative Breast Neoplasms* / drug therapy

Substances

  • Caspase 3
  • HCE
  • Indoles
  • Dieldrin